Carson Wealth (CWM LLC)
NBIX icon

Carson Wealth (CWM LLC)’s Neurocrine Biosciences NBIX Stock Holding History

Carson Wealth (CWM LLC)’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$16.7M Buy
126,740
+31,710
+33% +$4.21M 0.04% 385
2025
Q4 		$13.5M Buy
95,030
+11,306
+14% +$1.64M 0.04% 422
2025
Q3 		$11.8M Buy
83,724
+57,435
+218% +$7.78M 0.04% 419
2025
Q2 		$3.3M Buy
26,289
+15,786
+150% +$1.81M 0.01% 738
2025
Q1 		$1.16M Sell
10,503
-11,384
-52% -$1.44M ﹤0.01% 1051
2024
Q4 		$2.99M Buy
21,887
+14,003
+178% +$1.73M 0.01% 634
2024
Q3 		$908K Buy
7,884
+1,035
+15% +$142K ﹤0.01% 1094
2024
Q2 		$943K Buy
6,849
+2,185
+47% +$300K ﹤0.01% 931
2024
Q1 		$643K Buy
4,664
+1,762
+61% +$241K ﹤0.01% 1033
2023
Q4 		$382K Buy
2,902
+853
+42% +$98.2K ﹤0.01% 1163
2023
Q3 		$231K Buy
2,049
+664
+48% +$69.9K ﹤0.01% 1254
2023
Q2 		$131K Buy
1,385
+127
+10% +$12.4K ﹤0.01% 1431
2023
Q1 		$127K Sell
1,258
-42
-3% -$4.37K ﹤0.01% 1372
2022
Q4 		$155K Buy
1,300
+47
+4% +$5.5K ﹤0.01% 1196
2022
Q3 		$133K Buy
1,253
+245
+24% +$24.9K ﹤0.01% 1218
2022
Q2 		$98K Buy
1,008
+471
+88% +$43.5K ﹤0.01% 1324
2022
Q1 		$50K Buy
537
+328
+157% +$27.8K ﹤0.01% 1611
2021
Q4 		$18K Buy
+209
New +$19.2K ﹤0.01% 2054
2021
Q2 		$25K Hold
254
– – ﹤0.01% 1691
2021
Q1 		$25K Hold
254
– – ﹤0.01% 1691
2020
Q4 		$25K Hold
254
– – ﹤0.01% 1691
2020
Q3 		$25K Hold
254
– – ﹤0.01% 1691
2020
Q2 		$25K Hold
254
– – ﹤0.01% 1691
2020
Q1 		$25K Hold
254
– – ﹤0.01% 1690
2019
Q4 		$25K Hold
254
– – ﹤0.01% 1690
2019
Q3 		$25K Hold
254
– – ﹤0.01% 1690
2019
Q2 		$25K Hold
254
– – ﹤0.01% 1690
2019
Q1 		$25K Buy
254
+230
+958% +$19.2K ﹤0.01% 1689
2018
Q4 		$2K Buy
+24
New +$2.3K ﹤0.01% 1775

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Carson Wealth (CWM LLC)'s NBIX Position: Q1 2026 in Review

Carson Wealth (CWM LLC) increased its Neurocrine Biosciences (NBIX) stake by 33% in Q1 2026, buying an estimated $4.21M and bringing the position to 126,740 shares worth $16.7M. The position accounts for 0.04% of the portfolio, ranked #385.

Carson Wealth (CWM LLC) first reported a position in NBIX in Q4 2018 and has held it in 29 quarters since. 697 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

  • Carson Wealth (CWM LLC) held 126,740 shares of Neurocrine Biosciences worth $16.7M as of Q1 2026.
  • Carson Wealth (CWM LLC) bought 31,710 Neurocrine Biosciences shares in Q1 2026, an estimated $4.21M.
  • Neurocrine Biosciences made up 0.04% of Carson Wealth (CWM LLC)'s portfolio in Q1 2026, its #385 holding.
  • Carson Wealth (CWM LLC) first reported a position in Neurocrine Biosciences in Q4 2018 and has held it in 29 quarters since.
  • 697 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on Carson Wealth (CWM LLC)'s 13F filing for Q1 2026, filed 14 May 2026.